Opendata, web and dolomites

BraINstorm SIGNED

Engineered nanocarriers for simultaneous anticancer immune response and “switching” of tumor-associated macrophages for intranasal glioblastoma treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BraINstorm project word cloud

Explore the words cloud of the BraINstorm project. It provides you a very rough idea of what is the project "BraINstorm" about.

patient    expansion    care    invasive    size    generating    effect    tackle    chemical    parallel    physical    comprise    position    cancer    biocompatibility    surgery    invasiveness    crossing    adhesivity    treatment    stimulation    nose    clinically    survival    strategy    followed    model    turning    gbm    immunotherapeutic    taas    performed    immunomodulatory    50    combination    treat    types    peptides    explored    brain    education    therapies    conventional    oligonucleotides    oligonucleotide    memory    antigen    emerged    microenvironment    curable    radiotherapy    release    conjugates    intranasal    advantage    lasting    local    acid    macrophages    anticancer    brainstorm    resection    switch    m2    therapeutic    infiltrated    precludes    drug    appealing    promotes    assessing    blood    standard    vivo    barrier       reduces    explore    immunotherapy    tumor    ex    tam    immune    rate    preliminary    intrinsic    complexity    re    cpg    m1    storm    engineer    muco    regards    cells    chemotherapy    macrophage    administration    anti    prophylactic    disease    hyaluronic    mucosa    route    glioblastoma    immunoconjugates    nasal    tumoral    vitro   

Project "BraINstorm" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE CATHOLIQUE DE LOUVAIN 

Organization address
address: PLACE DE L UNIVERSITE 1
city: LOUVAIN LA NEUVE
postcode: 1348
website: www.uclouvain.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 166˙320 €
 EC max contribution 166˙320 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-06-01   to  2022-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) coordinator 166˙320.00

Map

 Project objective

Glioblastoma (GBM) remains a non-curable disease due to its high complexity and its position beyond the blood-brain barrier, which precludes access by conventional therapies. The current standard of care includes tumor resection surgery followed by radiotherapy or chemotherapy; an invasive process with a survival rate after five years is less than 5%. Tumor-associated macrophages (TAM) type 2 (M2 macrophages) comprise 30-50% of the infiltrated cells in GBM microenvironment and support tumor expansion. Immunotherapy represents an appealing strategy to treat several cancer types by turning the immune system against tumor cells; tumor antigen peptides (TAAs) recently emerged as an immunotherapeutic approach that can provide for a long-lasting immune response. Immunomodulatory oligonucleotides can “switch” M2 macrophages into M1 macrophages that produce an anti-tumoral effect. The BraINstorm (Brain INtranasal storm) project aims to engineer a hyaluronic acid (HA)-based combination conjugates that tackle GBM by the stimulation of the immune system via the delivery of TAAs and an immunomodulatory oligonucleotide (CpG) that promotes M2 macrophage “re-education” generating an “anticancer storm”. In parallel, taking advantage of the intrinsic muco-adhesivity of HA, BraINstorm will explore the nose-to-brain drug delivery, a more patient-friendly route that reduces the invasiveness. Novel combination immunoconjugates will be fully chemical-physical characterized and preliminary in vitro studies will be performed assessing the biocompatibility, drug release, and nasal mucosa barrier crossing in an ex-vivo model. Finally, the prophylactic and therapeutic activity of the HA-based conjugates will be in vivo explored in a clinically relevant GBM in vivo model through intranasal (IN) and local treatment administration with regards to effects on tumor size, immune memory, and survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINSTORM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRAINSTORM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

ICL CHROM (2020)

DNA interstrand crosslink repair and chromatin remodelling

Read More  

GENI (2019)

Gender, emotions and national identities: a new perspective on the abortion debates in Italy (1971-1981).

Read More